Encephalopathy refers to a broad range of brain dysfunctions caused by various factors, including liver disease, infections, and toxins. It accounts for a significant portion of neurological disorders worldwide, driving the demand for better therapies. Minimal hepatic encephalopathy (MHE), the early stage of hepatic encephalopathy (HE), affects 20% to 74% of patients globally. The growing focus on advanced encephalopathy therapeutics, such as novel drug candidates, is expected to fuel market growth in the coming years. With increasing research and development efforts, the pipeline is expected to expand, offering promising solutions for improved patient outcomes.
Major companies involved in the encephalopathy pipeline drugs market include Praxis Precision Medicines, Inc., Bausch Health, Inc., and others.
Leading drugs currently in the pipeline include Rifaximin SSD, LP352, RLS-0071, and others.
Increasing prevalence rates, rising public awareness of medical conditions, and continuous advancements in therapeutic research and drug development are driving the encephalopathy pipeline landscape.
The Encephalopathy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into encephalopathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for encephalopathy. The encephalopathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The encephalopathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with encephalopathy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to encephalopathy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Encephalopathy is a term for brain dysfunction caused by damage or disease affecting the brain. It occurs due to various factors such as liver failure, infections, toxins, lack of oxygen, or metabolic imbalances. This condition can lead to confusion, memory loss, and impaired cognitive function, ranging from mild symptoms to severe neurological impairment, depending on the underlying cause and its progression.
Encephalopathy treatments focus on managing the underlying cause. For hepatic encephalopathy, therapies include lactulose and rifaximin to reduce ammonia levels. Infections are treated with antibiotics, while metabolic imbalances require correcting electrolyte disturbances. Supportive care, including medications and dietary changes, is essential for symptom control and preventing further brain damage.
Encephalopathy drug pipeline analysis shows a rising focus on advanced therapeutics due to its increasing prevalence. Minimal hepatic encephalopathy (MHE), the early stage of hepatic encephalopathy (HE), affects 20% to 74% of patients globally. According to a study, around 44% of individuals with cirrhosis may develop HE within five years, with approximately 202,000 cases reported in the United States in 2018.
This section of the report covers the analysis of encephalopathy drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total encephalopathy clinical trials.
The drug molecule categories covered under the encephalopathy pipeline analysis include small molecules, biologics, cell therapies, gene therapies, peptides, and others. The encephalopathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for encephalopathy.
The EMR report for the encephalopathy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed encephalopathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in encephalopathy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for encephalopathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of encephalopathy drug candidates.
Rifaximin soluble solid dispersion (SSD), developed by Bausch Health Americas, Inc., is currently being evaluated in the Phase III RED-C clinical trial. This study aims to assess the efficacy and safety of rifaximin SSD-40mg IR in delaying the first episode of overt hepatic encephalopathy (OHE) decompensation in cirrhosis patients. The drug is designed to improve gastrointestinal solubility, preserve epithelial function, and reduce inflammation.
LP352 is currently being evaluated in a Phase 3 clinical trial to assess its efficacy, safety, and tolerability in treating seizures in children and adults with developmental and epileptic encephalopathies (DEE). LP352 is a 5-HT2C receptor superagonist designed to reduce seizures in conditions like Dravet syndrome, Lennox-Gastaut syndrome, and CDKL5 deficiency disorder. The study is expected to be completed by November 2026.
RLS-0071 is a novel peptide drug sponsored by ReAlta Life Sciences, Inc., currently in Phase 2 clinical trials. This study aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of RLS-0071 in newborns with moderate or severe hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia. The trial is expected to conclude by April 2026 with an estimated 42 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Encephalopathy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for encephalopathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into encephalopathy collaborations, regulatory environments, and potential growth opportunities.
Hepatic Encephalopathy Treatment Market Report and Forecast
Overt Hepatic Encephalopathy Drug Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share